Glaxo award winner getting more out of LIF
15 April, 2004 by Melissa TrudingerProf Doug Hilton, a researcher at the Walter and Eliza Hall Institute in Melbourne, has been awarded this year's GlaxoSmithKline award for research excellence, for his work on cell signalling.
J&J profit jumps, earnings forecast raised
14 April, 2004 by Staff WritersJohnson & Johnson's first-quarter earnings have jumped 20 per cent on higher sales of prescription drugs and medical devices, prompting it to raise its full-year profit forecast.
Biotech Capital kicks off expansion plans with $3.8m buyback
14 April, 2004 by Renate KrelleShareholders of Biotech Capital (ASX:BTC) have approved a $3.8 million buyback of shares and options held by the Challenger Group.
Gradiflow graduates to validation stage
14 April, 2004 by Melissa TrudingerLife Technologies (formerly Gradipore, ASX: GDP) has announced that it has moved into the second phase of its development agreement with US company Hematech.
Biotech startup Epichem opens for business
13 April, 2004 by Melissa TrudingerState of the art medicinal chemistry facilities were opened on the Murdoch University campus by the WA Minister for Development Clive Brown last week for biotech start up Epichem.
Ventracor ramps up manufacturing capacity for European trials
13 April, 2004 by Renate KrelleVentracor (ASX:VCR) today announced it has commissioned a new facility for manufacturing its VentrAssist artificial heart device. VCR will expand its current clean-room space, establishing a 260 square meter clean room and manufacturing facility in Sydney’s Chatswood.
Prana surges on study validating its metal-ion theory
13 April, 2004 by Graeme O'NeillShares in Melbourne drug-discovery company Prana Biotechnology (ASX:PBT, NASDAQ:PRAN) have surged by some 30 per cent after the Journal of Neuroscience published a new study last week that further validates the metal-ion theory of Alzheimer’s developed by Prana founder and Dr Ashley Bush.
Eiffel moves to Sydney
08 April, 2004 by Renate KrelleMelbourne’s loss was Sydney’s gain today, when drug re-engineering company Eiffel Technologies (ASX:EIF) announced it would be upping stakes and moving its head office to Sydney’s biotechnology neighbourhood of North Ryde, adjoining its new semi-commercial production facility.
Norwood to back animal conservation research
07 April, 2004 by Melissa TrudingerMelbourne biotech Norwood Abbey (ASX:NAL) is to sponsor a Monash Institute of Reproduction and Development group dedicated to research into the conservation and preservation of Australian animals.
GroPep cans ulcer treatment after Phase II
07 April, 2004 by Graeme O'NeillAdelaide biotech GroPep (ASX:GRO) has yanked its potential topical treatment for chronic venous ulcers after inconclusive results from a Phase II clinical trial.
Biosignal lists on ASX at premium
06 April, 2004 by Renate KrelleBiosignal (ASX:BOS) listed today on the Australian Stock Exchange, with shares leaping to AUD$0.38, a premium of almost 100 per cent on its $0.20 issue price.
New neuro labs open in Melbourne
06 April, 2004 by Melissa TrudingerA state-of-the-art cellular neurophysiology laboratory was opened today at the University of Melbourne for the National Neuroscience Facility (NNF).
GeneTraks picks up $1m grant
06 April, 2004 by Melissa TrudingerBrisbane-based GeneTraks has received a $1 million R&D Start grant from the Commonwealth government for its AUD$2.6 million equine diagnostics development project.
Phosphagenics claims success in morphine trial
06 April, 2004 by Renate KrellePhosphagenics (ASX:POH) -– formerly Vital Capital -– has announced the successful completion of animal studies for its transdermal delivery system for morphine.
Biotopya entrepreneurs blitz awards, sell company
05 April, 2004 by Melissa TrudingerA company formed as part of the Victorian Biotechnology Entrepreneur Program, a pilot program of Young Achievers Australia and the Victorian State Government, has returned a whopping 900 per cent to its shareholders, through the sale of its products to a scientific supplies company.
